Monopar Therapeutics Inc - Asset Resilience Ratio
Monopar Therapeutics Inc (MNPR) has an Asset Resilience Ratio of 61.56% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MNPR net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Monopar Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MNPR total assets.
Liquid Assets Composition Over Time
This chart breaks down Monopar Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Monopar Therapeutics Inc carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $84.95 Million | 61.56% |
| Total Liquid Assets | $84.95 Million | 61.56% |
Asset Resilience Insights
- Very High Liquidity: Monopar Therapeutics Inc maintains exceptional liquid asset reserves at 61.56% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Monopar Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Monopar Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Monopar Therapeutics Inc (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Monopar Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 55.83% | $78.57 Million | $140.72 Million | +31.95pp |
| 2024-12-31 | 23.88% | $14.40 Million | $60.29 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $7.35 Million | -- |
| 2022-12-31 | 37.30% | $4.93 Million | $13.23 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $20.52 Million | -- |
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more